Global Cancer Technology

Global Cancer Technology

Early Stage

GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.

GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.

Overview

Raised this Round: Raised: $0

Total Commitments ($USD)

Platform

Netcapital

Start Date

02/07/2022

Close Date

04/29/2022

Min. Goal
$10,000
Max. Goal
$1,070,000
Min. Investment

$100

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.00

Pre-Money Valuation

$26,682,636

Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

High

Location

San Diego, California

Business Type

Growth

Global Cancer Technology, with a valuation of $26.6 million, is raising funds on NetCapital. The company has acquired multiple patented technologies currently being tested as a novel treatment for deadly diseases. The technology is presently focused on detecting and treating brain cancer and includes scintillating nanoparticles, cancer biomarkers, and cancer inhibitors. Global Cancer Technology is working with world-renowned scientists of the Barrow Neurological Institute, Baylor Scott & White Hospital, and University of California San Diego. John P. Clark founded Global Cancer Technology in May 2017. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,070,000. The campaign proceeds will be used for research and development, university scientific consulting, and general and administrative costs.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-739,118

$-674,005

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$49,137

$1,071

Accounts Receivable

$0

$0

Total Assets

$51,964

$251,420

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Financials as of: 02/07/2022
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Global Cancer Technology 04/28/2022 Netcapital $26,682,636 $0 Equity - Common Not Funded RegCF
Global Cancer Technology 09/07/2021 Dalmore Group - $24,400 Equity - Common Funded RegA+
Global Cancer Technology 02/24/2020 Netcapital $11,571,400 $107,000 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Global Cancer Technology on NetCapital 2022
Platform: Netcapital
Security Type: Equity - Common
Valuation: $26,682,636
Price per Share: $2.00

Follow company

Follow Global Cancer Technology on NetCapital 2022

Buy Global Cancer Technology's Deal Report

Warning: according to the close date for this deal, Global Cancer Technology may no longer be accepting investments.

Global Cancer Technology Deal Report

Get KingsCrowd’s comprehensive report on Global Cancer Technology including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Global Cancer Technology is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Global Cancer Technology deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge